← Back to Search

Progestin

Levonorgestrel-based emergency contraception 3.0mg for Obesity (EC-Obesity Trial)

Phase 4
Waitlist Available
Led By Alison Edelman, MD, MPH
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 days
Awards & highlights

EC-Obesity Trial Summary

This trial is testing a new dose of emergency contraception for obese women, who are more likely to experience failure with the current dose.

Eligible Conditions
  • Obesity

EC-Obesity Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Number of Participants in Two Treatment Groups (1.5mg Levonorgestrel and 3mg Levonorgestrel) With no Follicle Rupture at 5 Days Within One Menstrual (Treatment) Cycle.
Secondary outcome measures
Number of Participants With Follicle Rupture Before 5 Days

Side effects data

From 2021 Phase 4 trial • 70 Patients • NCT02863445
9%
Upper Respiratory Infection
9%
Nausea
6%
Menstrual Cramping
6%
Abdominal Cramping
6%
Common Cold
3%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
LNG-ECx1
LNG-ECx2

EC-Obesity Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: LNG-ECx2Experimental Treatment1 Intervention
Levonorgestrel 3mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
Group II: LNG-ECx1Active Control1 Intervention
Levonorgestrel 1.5 mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Levonorgestrel-based emergency contraception 3.0mg
2017
Completed Phase 4
~70

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
973 Previous Clinical Trials
6,845,959 Total Patients Enrolled
29 Trials studying Obesity
9,276 Patients Enrolled for Obesity
National Institutes of Health (NIH)NIH
2,696 Previous Clinical Trials
6,952,509 Total Patients Enrolled
103 Trials studying Obesity
25,786 Patients Enrolled for Obesity
Alison Edelman, MD, MPHPrincipal InvestigatorOregon Health and Science University
7 Previous Clinical Trials
314 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
ContraceptionJournal
Impact of Obesity on the Pharmacokinetics of Levonorgestrel-based Emergency Contraception: Single and Double Dosing
Edelman, Alison B., Ganesh Cherala, Steven W. Blue, David W. Erikson, and Jeffrey T. Jensen. 2016. “Impact of Obesity on the Pharmacokinetics of Levonorgestrel-based Emergency Contraception: Single and Double Dosing”. Contraception. Elsevier BV. doi:10.1016/j.contraception.2016.03.006.
clinicaltrials.govStudy
Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG
Alison Edelman 2017. "Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02863445.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top